Oak Park, IL, United States of America

Mark Lingen

USPTO Granted Patents = 6 



Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2013-2017

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Mark Lingen: Innovator in Opioid Antagonist Research

Introduction

Mark Lingen is a prominent inventor based in Oak Park, Illinois. He has made significant contributions to the field of medical research, particularly in the use of opioid antagonists. With a total of six patents to his name, Lingen's work focuses on innovative methods to combat cellular proliferation and cancerous growth.

Latest Patents

Lingen's latest patents include groundbreaking methods for using opioid antagonists to attenuate cellular proliferation and migration. One of his notable inventions provides methods for inhibiting endothelial cell proliferation and migration, which is crucial in the context of angiogenesis. This invention aims to reduce cancerous tumor growth and metastasis through the application of peripherally restricted opioid antagonists. Another patent emphasizes similar methods, reinforcing the potential of opioid antagonists in medical treatments.

Career Highlights

Mark Lingen is affiliated with the University of Chicago, where he continues to advance his research. His work has garnered attention for its potential impact on cancer treatment and cellular behavior. Lingen's innovative approaches have positioned him as a key figure in the intersection of pharmacology and oncology.

Collaborations

Lingen collaborates with esteemed colleagues, including Jonathan Moss and Patrick A Singleton. These partnerships enhance the research environment and contribute to the development of new therapeutic strategies.

Conclusion

Mark Lingen's contributions to the field of opioid antagonist research highlight his commitment to advancing medical science. His innovative patents and collaborations reflect a dedication to improving treatment options for cancer and related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…